Clinical trial
Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination…
NCT00288431 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00288431 |
|---|---|
| Title | Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015) |
| Official title | A Phase 1B, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Ariad Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer, Sarcoma |
| Intervention type | Drug |
| Interventions | ridaforolimus, Doxorubicin |
| Enrollment | 37 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Feb 8, 2006 |
| Last update posted | Jul 22, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: